Indivior (NASDAQ:INDV – Get Free Report)‘s stock had its “overweight” rating reaffirmed by Piper Sandler in a report issued on Friday, Benzinga reports. They currently have a $16.00 target price on the stock, up from their prior target price of $15.00. Piper Sandler’s price objective points to a potential upside of 76.60% from the company’s previous close.
Separately, Craig Hallum reduced their price target on shares of Indivior from $20.00 to $16.00 and set a “buy” rating on the stock in a research report on Friday, October 11th.
Check Out Our Latest Analysis on Indivior
Indivior Price Performance
Indivior (NASDAQ:INDV – Get Free Report) last announced its quarterly earnings data on Thursday, July 25th. The company reported $0.44 EPS for the quarter, beating the consensus estimate of $0.40 by $0.04. The firm had revenue of $299.00 million for the quarter, compared to analyst estimates of $285.90 million. Indivior had a negative return on equity of 654.82% and a negative net margin of 12.29%. As a group, equities research analysts anticipate that Indivior will post 1.7 EPS for the current fiscal year.
Institutional Trading of Indivior
Several hedge funds have recently added to or reduced their stakes in the business. Toronto Dominion Bank lifted its stake in shares of Indivior by 58.0% in the 1st quarter. Toronto Dominion Bank now owns 2,094,865 shares of the company’s stock valued at $44,872,000 after acquiring an additional 769,000 shares during the last quarter. Susquehanna International Group Ltd. bought a new stake in Indivior in the second quarter valued at approximately $3,224,000. Millennium Management LLC boosted its stake in shares of Indivior by 48.1% during the second quarter. Millennium Management LLC now owns 493,313 shares of the company’s stock valued at $7,952,000 after purchasing an additional 160,282 shares during the period. Mediolanum International Funds Ltd bought a new position in shares of Indivior in the third quarter worth approximately $1,240,000. Finally, M&G Plc purchased a new position in shares of Indivior in the first quarter worth $2,518,000. 60.33% of the stock is owned by institutional investors.
Indivior Company Profile
Indivior PLC, together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and co-occurring disorders in the United States, the United Kingdom, and internationally. The company develops medicines to treat substance use disorders, serious mental illnesses, and opioid overdose.
Recommended Stories
- Five stocks we like better than Indivior
- Industrial Products Stocks Investing
- Texas Roadhouse Stock Steering for New Highs This Year
- How to Use the MarketBeat Stock Screener
- Monopar Therapeutics Skyrockets 400% on Licensing Deal
- How the NYSE and NASDAQ are Different, Why That Matters to Investors
- Tractor Supply Stock Pulls Back: A Prime Buying Opportunity
Receive News & Ratings for Indivior Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Indivior and related companies with MarketBeat.com's FREE daily email newsletter.